ABSTRACT

Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic inflammation causing swelling in the joints. IL- 17/TNF-α bispecific antibodies are antibodies that can bind to two different types of epitopes and work on two different types of receptors. IL-17/TNF-α bispecific antibodies have anti-inflammatory effects that act by blocking the inflammatory pathways of rheumatoid arthritis. Thus, bispecific antibodies have the potential to be the latest effective therapy against rheumatoid arthritis.

Keywords: Bispecific antibodies, rheumatoid arthritis, therapeutics